Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

CNBC host Jim Cramer continues to pound the table on Eli Lilly’s (LLY) stock. The host of the TV show “Mad Money” continues to be a cheerleader for LLY stock, saying repeatedly that the pharmaceutical ...

Eli Lilly Cuts Insulin Prices We don’t expect Eli Lilly’s LLY decision to cut insulin prices by 70% to have a significant impact on our $289 fair value estimate for the company.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

Eli Lilly will cut prices for some older insulins later this year and immediately give more patients access to a cap on costs they pay to fill prescriptions. (AP Photo/Pablo Salinas) The moves ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $1,000.00. Don't Miss our Black Friday Offers: Mohit ...

Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, ... It has now addressed all these concerns. Zepbound's price cuts can make at least some customers happy, ...

In January, Sen. Ron Wyden of Oregon said there was no clear reason “why the list price of Eli Lilly’s main insulin drug, Humalog, went from $21 a vial in 1996 to its current list price of ...

Eli Lilly currently has a forward P/E of over 45x. This valuation is higher than the sector average. Read more to see proposed pair trade between XPH and LLY.

It's rare for a business to warn investors that worse-than-expected earnings are coming without taking a hit to its share price, but in its third-quarter release on Nov. 2, Eli Lilly (LLY-0.12% ...

We don’t expect Eli Lilly’s decision to cut insulin prices by 70% to have a significant impact on our $289 fair value estimate for the company. Even though insulins represent over 15% of total ...